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Introduction: Annually, 1.4 million women worldwide are diag-
nosed with breast cancer (BC) and are at risk for another common 
malignancy: non–small-cell lung cancer (NSCLC). No large popula-
tion-based study has examined subsequent survival.
Methods: Women with histologically confirmed NSCLC after BC 
(BC-NSCLC, n = 3529) were identified in SEER-18 registries (1988–
2009). Clinicopathologic characteristics and survival outcomes were 
compared among women with first primary NSCLC (NSCLC-1, 
n = 151,628). Cox regression analyses were adjusted for patient, BC, 
and NSCLC factors.
Results: BC-NSCLC was diagnosed at earlier stages (34% local-
ized, 30% regional, 36% distant) than NSCLC-1 (22%, 28%, 
and 50%, respectively; p < 0.0001). For localized and regional 
BC-NSCLC, surgical resection rates were higher than NSCLC-1 
(72% versus 69% [p < 0.01] and 56% versus 46% [p < 0.0001]), 
respectively). Radiotherapy was given less often for BC-NSCLC 
than NSCLC-1 (localized: 15% versus 18%, p < 0.004; regional: 
38% versus 49%, p < 0.0001). Median overall survival (OS) after 
localized, regional, and distant BC-NSCLC was 5.1 years, 1.9 
years, and 5.8 months, respectively. For NSCLC-1, median OS was 
4.6 years, 1.5 years, and 4.6 months, respectively. BC history did 
not affect OS for localized NSCLC, and OS was modestly greater 
after regional (p = 0.016) and distant (p < 0.0001) BC-NSCLC 
compared with NSCLC-1. BC radiotherapy to the ipsilateral chest 
did not unfavorably influence OS.
Conclusions: BC survivors are more likely to be diagnosed with 
earlier stage NSCLC versus first primary NSCLC patients, perhaps 
reflecting heightened surveillance compared with the general popu-
lation. In contrast to prior studies of NSCLC in survivors of lympho-
poietic malignancies, BC history does not appear to adversely affect 
OS after NSCLC.
Key Words: Breast cancer, Lung cancer, Second malignant 
neoplasms
(J Thorac Oncol. 2014;9: 1081–1090)
Breast cancer (BC) is the most common malignancy among US women, with an estimated 232,670 cases expected 
in 2014.1 Advances in the detection, treatment, and manage-
ment of BC over the past few decades have resulted in marked 
improvements in survival, resulting in a growing number of 
women at risk for the late effects of cancer and its treatment.2 
As of 2012, women with BC accounted for 22% of cancer 
survivors in the United States, representing a population of 
over 2.9 million,3 which is anticipated to grow further in the 
next few decades.
BC survivors and other cancer survivors are at risk for 
developing other malignancies.4 In fact, second and higher 
order cancers now comprise the most common incident cancer 
in the United States, representing 18% (or almost one in five 
of all new cancers),5 and propelling the study of second malig-
nant neoplasms (SMN) onto the National Cancer Institute’s 
List of Provocative Questions.6 Following a diagnosis of BC, 
lung cancer accounts for the largest number of second non-
breast malignancies,4 and given its lethality, represents the 
most common non-BC cause of death after cardiac and vas-
cular causes.7–9
Although a number of studies have examined the risk 
of developing lung cancer after BC10–20 and have analyzed 
risk factors (reviewed in Lorigan et al.),21 there are no large 
investigations of subsequent survival. One study of outcomes 
in BC survivors with second primary lung cancer included 
only 6 patients,22 and another included 35 patients.23 No large, 
population-based study has comprehensively examined out-
comes among BC survivors with second primary non–small-
cell lung cancer (NSCLC), taking into account demographic, 
clinicopathologic, and other variables. It is important to evalu-
ate these outcomes, given the significantly inferior survival 
recently reported for patients with lymphopoietic malignan-
cies, including Hodgkin lymphoma (HL) and chronic lympho-
cytic leukemia (CLL), who develop NSCLC.24,25 Although the 
inferior survival24,25 among these patients may be due in part to 
inherent immune deficiencies associated with some lympho-
cytic malignancies,25,26 to our knowledge a diagnosis of BC 
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is not associated with immunocompromisation. Moreover, the 
public health impact of any factor that might lessen the oth-
erwise excellent long-term prognosis for BC survivors3 would 
only underscore the need for future research into underlying 
pathways and efforts at prevention and intervention.27–30
METHODS
Patients
All women diagnosed with histologically confirmed 
NSCLC as a SMN after a first BC (excluding those with dis-
tant disease) were identified in population-based registries 
of the Surveillance, Epidemiology, End Results (SEER) 18 
Program (1988–2009). The SEER program registries capture 
about 28% of the US population. For our study, a minimum 
latency of 2 months was required, as used in SEER to exclude 
synchronous primary cancers.31 The resultant 3529 patients 
(BC-NSCLC) were grouped by SEER Historic Stage of local-
ized (i.e., confined to lung or bronchial tree with no regional 
extension or nodal or distant metastases), regional (i.e., ipsilat-
eral regional nodes and/or extension to regional sites), or dis-
tant (i.e., metastasis to contralateral thoracic or distant nodes, 
malignant pericardial or pleural effusions, distant metastases, 
and/or extension to sites such as heart, abdomen, spine, con-
tralateral lung, skeletal muscle, skin, and brachial plexus) 
stage NSCLC. This staging is described in detail in historic 
SEER coding manuals (http://seer.cancer.gov/tools/coding-
manuals/historical.html). Because SEER did not record lung 
cancer stage before 1988, study entry began in 1988. For the 
NSCLC-1 comparison group, all female patients diagnosed 
with a first primary NSCLC (n = 151,628) were identified 
from the same registries during 1988–2009. Eligible NSCLC 
histologies were squamous cell carcinoma, adenocarcinoma, 
bronchiolo-alveolar carcinoma, adenosquamous carcinoma, 
large cell carcinoma, and non–small-cell carcinoma, not oth-
erwise specified (histology codes listed in Table 1).
The SEER Program records sociodemographic param-
eters for each patient’s county of residence, as determined from 
census data, from which we considered the proportion of adults 
aged 25 years and older, residing within that county with less 
than a high-school education, and the cost of living adjusted 
median income as measures of socioeconomic status.32,33
Restriction to Histologically Confirmed NSCLC
In view of the strict criteria that the SEER program 
applies to define SMN (http://seer.cancer.gov/tools/mph-
rules/), our study was restricted to histologically confirmed 
NSCLC. Despite these stringent criteria, a small percentage 
of BC-NSCLC adenocarcinoma may represent metastatic BC. 
Although to our knowledge an independent verification of 
NSCLC adenocarcinoma in the SEER program has not been 
undertaken, in a recent pathology review of lung cancer in BC 
survivors in the Swedish Cancer Registry, misclassification of 
lung metastases as new primaries diminished with calendar-
year period to less than 5% for BC diagnosed in 1980.34 Our 
study included only BC patients diagnosed in 1988 or later. 
Thus, in view of the improvements in histologic diagnostic 
procedures with time, and the rigorous criteria that the SEER 
program requires to define SMN,35 we estimate that any effects 
of residual misclassification are small.
Statistical Analysis
Frequency distributions of variables were compared using 
Fisher’s Exact test, with continuous variables first being trans-
formed into categorical variables (for these analyses only). 
Overall survival (OS; i.e., all-cause) was estimated using Kaplan-
Meier methods, with survival times measured from date of 
NSCLC diagnosis until date of death or last follow-up (through 
December 31, 2009). To compare OS between BC-NSCLC and 
NSCLC-1, both the log-rank and supremum log-rank36 tests were 
used; in comparison to the log-rank test, the power of the supre-
mum log-rank test is less sensitive to the presence of nonpropor-
tional hazards (e.g., when survival curves cross). Lung cancer 
cause-specific survival (LC-CSS) time was measured from date 
of NSCLC diagnosis until date of death or last follow-up (through 
December 31, 2009); here, only death from lung cancer was des-
ignated as an event. The SEER program abstracts data from death 
certificates to derive a single cause of death. For OS and LC-CSS, 
Cox regression (controlling for covariates) was also used for sur-
vival comparisons. LC-CSS analyses were further complemented 
by regression analyses of cumulative incidence using the propor-
tional subdistribution hazard regression model of Fine and Gray.37 
For BC-NSCLC, the stage-specific effect of radiotherapy for BC 
on survival outcomes after developing an ipsilateral NSCLC 
was assessed by the stratified log-rank test, stratified by year of 
diagnosis (i.e., 1988–1998 versus 1999–2009). All analyses were 
conducted using the R statistical software package.38 All p values 
were two-sided, with p < 0.05 defined as statistically significant, 
as in prior studies of survival after second malignancies.24,33
RESULTS
Patient and Tumor Characteristics
Table 1 outlines demographic and clinicopathologic 
characteristics at BC diagnosis, grouped by subsequent 
NSCLC stage. Among the NSCLC stage groups, the distribu-
tions of age, BC stage, estrogen receptor (ER) status, grade, 
and type of BC surgery within each stage were similar. No 
difference in the proportion of women given radiotherapy 
initially was evident (p = 0.18, omitting unknown status). 
Black women were slightly overrepresented among distant 
BC-NSCLC (p = 0.006). Women with localized (versus more 
advanced) NSCLC more likely had BC in 2000–2009.
Table 2 outlines clinicopathologic characteristics of 
BC-NSCLC and NSCLC-1 patients at NSCLC diagnosis. The 
NSCLC stage distribution of BC-NSCLC (34% localized, 36% 
distant), differed significantly (p < 0.00001) from NSCLC-1 
(22% localized, 50% distant). BC-NSCLC was diagnosed in 
more recent years and at slightly more advanced ages than 
NSCLC-1, reflecting its SMN nature. The prevalence of lung 
adenocarcinoma among BC-NSCLC patients with localized or 
regional disease was slightly greater than for NSCLC-1. Women 
with either localized or regional BC-NSCLC were considerably 
more likely to undergo cancer-directed surgery than NSCLC-1 
patients, with corresponding percentages of 72% and 69% 
(p = 0.004), and 56% and 46%, respectively (p < 0.0001). At 
1083Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014 NSCLC After Breast Cancer
TABLE 1.  Patient and Tumor Characteristics at Time of Breast Cancer Diagnosis Among 3529 Women Who Subsequently 
Developed a Histologically Confirmed Second Primary Non–Small-Cell Lung Cancer (NSCLC)
NSCLC
Total Localized Regional Distant p Valuea
Breast cancerb
  Total 3529 (100%) 1215 1042 1272
Age (years) 0.11
  ≤49 312 (9%) 88 (7%) 93 (9%) 131 (10%)
  50–59 706 (20%) 235 (19%) 199 (19%) 272 (21%)
  60–69 1303 (37%) 453 (37%) 405 (39%) 445 (35%)
  70–79 981 (28%) 356 (29%) 279 (27%) 346 (27%)
  ≥80 227 (6%) 83 (7%) 66 (6%) 78 (6%)
Race 0.006
  Black 306 (9%) 86 (7%) 80 (8%) 140 (11%)
  White 3049 (86%) 1070 (88%) 905 (87%) 1074 (84%)
  Otherc 173 (5%) 58 (5%) 57 (5%) 58 (5%)
  Unknownd 1 (0.03%) 1 (0.1%) 0 0
Stage 0.33
  Localized 2571 (73%) 882 (73%) 745 (71%) 944 (74%)
  Regional 958 (27%) 333 (27%) 297 (29%) 328 (26%)
Estrogen receptor status 0.38
  Positive 2175 (62%) 772 (64%) 650 (62%) 753 (59%)
  Borderline positive 16 (0.5%) 4 (0.3%) 5 (0.5%) 7 (0.6%)
  Negative 611 (17%) 194 (16%) 179 (17%) 238 (19%)
  Unknownd 727 (21%) 245 (20%) 208 (20%) 274 (22%)
Grade 0.43
  Well differentiated 624 (18%) 236 (19%) 170 (16%) 218 (17%)
  Moderately 
differentiated
1287 (36%) 448 (37%) 394 (38%) 445 (35%)
  Poorly differentiated 992 (28%) 328 (27%) 297 (29%) 367 (29%)
  Undifferentiated; 
anaplastic
70 603 (2%) 21 (2%) 19 (2%) 30 (2%)
  Unknownd 556 (16%) 182 (15%) 162 (16%) 212 (17%)
Year of diagnosis <0.0001
  1988–1999 1825 (52%) 564 (46%) 563 (54%) 698 (55%)
  2000–2009 1704 (48%) 651 (54%) 479 (46%) 574 (45%)
Type of breast cancer 
surgerye
0.11
  Mastectomy 1636 (46%) 534 (44%) 499 (48%) 603 (47%)
  Partial mastectomy 1852 (52%) 669 (55%) 534 (51%) 649 (51%)
  No surgery 39 (1%) 12 (1%) 9 (1%) 18 (1%)
Radiotherapy for breast 
cancer
0.01
  Yes 1637 (46%) 582 (48%) 469 (45%) 586 (46%)
  No 1814 (51%) 593 (49%) 558 (54%) 663 (52%)
  Unknown 78 (2%) 40 (3%) 15 (1%) 23 (2%)
ap values from Fisher’s exact test.
bICD codes 8500/3-8550/3.
dFisher’s exact test, with the omission of the unknown variable, changes p values but not the qualitative results (i.e., significant versus not significant) except for “Radiotherapy for 
breast cancer” which was no longer significant (p = 0.18) after omission of “unknown”.
cAmerican Indian, Alaskan Native or Asian/Pacific Islander.
eMastectomy includes any surgical procedure in which all ipsilateral breast tissue was removed; partial mastectomy includes surgical procedures in which the gross tumor and some 
breast tissue were removed. Patients who were categorized by the SEER Program as either undergoing unspecified breast cancer surgery (n = 1) or for whom it was unknown whether 
surgery was performed (n = 1) are not shown.
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(Continued )
TABLE 2.  Patient and Tumor Characteristics at Time of Non–Small-Cell Lung Cancer (NSCLC) Diagnosis
Localizeda Regionala Distanta
BC-NSCLC NSCLC-1 BC-NSCLC NSCLC-1 BC-NSCLC NSCLC-1
Totalb 1215 33,860 1042 41,512 1272 76,256
Age (years)
  ≤49 36 (3%) 1425 (4%) 33 (3%) 2694 (6%) 42 (3%) 6552 (9%)
  50–59 128 (11%) 4666 (14%) 124 (12%) 6886 (17%) 150 (12%) 13,559 (18%)
  60–69 368 (30%) 10,232 (30%) 312 (30%) 12,655 (30%) 343 (27%) 21,313 (28%)
  70–79 491 (40%) 12,278 (36%) 396 (38%) 13,913 (34%) 472 (37%) 22,809 (30%)
  ≥80 192 (16%) 5259 (16%) 177 (17%) 5364 (13%) 265 (21%) 12,053 (16%)
Median 71 70 71 69 71 68
p = 0.0006 p < 0.0001 p < 0.0001
Race
  Black 86 (7%) 2944 (9%) 80 (8%) 4355 (10%) 140 (11%) 8887 (11%)
  White 1070 (88%) 29,221 (86%) 905 (87%) 35,001 (84%) 1074 (84%) 61,767 (82%)
  Other 58 (5%) 1646 (5%) 57 (5%) 2114 (5%) 58 (5%) 5507 (7%)
  Unknownc 1 (0.1%) 49 (0.1%) 0 42 (0.1%) 0 95 (0.1%)
p = 0.23 p = 0.02 p = 0.0007
NSCLC histologyd
  Squamous cell carcinoma 294 (24%) 8985 (27%) 295 (28%) 12,405 (30%) 209 (16%) 13,380 (18%)
  Adenocarcinoma 585 (48%) 14,909 (44%) 475 (46%) 17,746 (43%) 634 (50%) 40,507 (53%)
  Bronchiolo-alveolar 
carcinoma
174 (14%) 4836 (14%) 67 (6%) 2126 (5%) 35 (3%) 1910 (3%)
  Adenosquamous carcinoma 22 (2%) 666 (2%) 21 (2%) 932 (2%) 16 (1%) 832 (1%)
  Large cell carcinoma 41 (3%) 1632 (5%) 49 (7%) 2759 (7%) 60 (6%) 5132 (8%)
  NSCLC, NOSc 99 (8%) 2832 (8%) 135 (13%) 5544 (13%) 318 (25%) 14,495 (19%)
p = 0.03 p = 0.03 p < 0.0001
NSCLC grade
  Well differentiated 177 (15%) 4541 (13%) 60 (6%) 1954 (5%) 30 (2%) 1847 (2%)
  Moderately differentiated 411 (34%) 10,397 (31%) 261 (25%) 9721 (23%) 150 (12%) 7493 (10%)
  Poorly differentiated 341 (28%) 9911 (29%) 397 (38%) 15,613 (38%) 339 (26%) 21,919 (29%)
  Undifferentiated; anaplastic 37 (3%) 1062 (3%) 35 (4%) 1836 (4%) 31 (3%) 2885 (4%)
  Unknownc 249 (20%) 7949 (23%) 289 (28%) 12,388 (30%) 722 (57%) 42,112 (55%)
p = 0.04 p = 0.10 p = 0.008
Year of diagnosis
  1988–1999 208 (17%) 9454 (28%) 195 (19%) 12,223 (29%) 158 (12%) 19,367 (25%)
  2000–2009 1007 (83%) 24,406 (72%) 847 (81%) 29,289 (71%) 1114 (88%) 56,889 (75%)
p < 0.0001 p < 0.0001 p < 0.0001
Cancer-directed surgery for NSCLC
  Yes 878 (72%) 23,273 (69%) 584 (56%) 19,093 (46%) 91 (7%) 5712 (7%)
  No 335 (28%) 10,355 (31%) 455 (44%) 22,158 (53%) 1179 (93%) 70,159 (93%)
  Unknownc 2 (0.2%) 232 (0.7%) 3 (0.3%) 261 (0.6%) 2 (0.2%) 385 (0.5%)
p = 0.004 p < 0.0001 p = 0.20
Radiotherapy for NSCLC
  Yes 180 (15%) 6123 (18%) 392 (38%) 20,292 (49%) 516 (41%) 35,699 (47%)
  No 1021 (84%) 27,109 (80%) 622 (60%) 20,285 (49%) 735 (58%) 39,179 (51%)
  Unknownc 14 (1%) 628 (2%) 28 (3%) 935 (2%) 21 (2%) 1378 (2%)
p = 0.001 p < 0.0001 p < 0.0001
Laterality of NSCLC relative to BC: patients who underwent breast radiotherapye
  Ipsilateral 285 (49%) NA 231 (50%) NA 281 (51%) NA
  Contralateral 294 (51%) NA 232 (50%) NA 257 (46%) NA
  Bilateral lung cancer 0 NA 1 (<1%) NA 15 (3%) NA
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the same time, BC-NSCLC patients with either localized or 
regional NSCLC were less likely to receive radiotherapy for 
NSCLC than NSCLC-1 patients, with corresponding per-
centages of 15% and 18% (p = 0.001), and 38% and 49% 
(p < 0.0001), respectively.
Median latencies between diagnoses of BC and local-
ized, regional, and distant NSCLC were 3.9, 4.3, and 5.5 years 
(p < 0.004, Kruskal-Wallis test), respectively, likely reflect-
ing the influence of closer medical follow-up of BC survivors 
(compared with the general population) in detecting NSCLC 
at earlier stages and at a shorter time after BC diagnosis.
Vital Status and Cause of Death in 
Women with BC-NSCLC and NSCLC-1
Table 3 shows vital status and cause of death 
grouped by NSCLC and also by calendar year of NSCLC 
diagnosis (1988–1998 and 1999–2009). For each NSCLC 
stage, mortality due to lung cancer accounted for most 
deaths and was observed to be greater among NSCLC-1. 
Notably, the combined percentage of lung and BC deaths 
was similar between BC-NSCLC and NSCLC-1. Heart 
disease accounted for a small number (n = 98) of deaths, 
comprising 5% and 3% of deaths, respectively, among BC 
patients given radiotherapy for left-sided and right-sided 
BC, respectively. Cardiovascular deaths among NSCLC-1 
patients (4% overall) were similar to BC-NSCLC patients 
for each stage subgroup.
Survival of BC-NSCLC Compared with NSCLC-1
Figure 1 and Table 4 show the unadjusted OS of 
BC-NSCLC compared with NSCLC-1, grouped by NSCLC 
stage. For each NSCLC stage, OS was greater for BC-NSCLC 
Laterality of NSCLC relative to BC: patients who did not undergo breast radiotherapye
  Ipsilateral 314 (53%) NA 279 (50%) NA 313 (50%) NA
  Contralateral 278 (47%) NA 278 (50%) NA 296 (47%) NA
  Bilateral lung cancer 0 NA 0 NA 20 (3%) NA
Latencyf
  ≥2 months to 2 years 374 (31%) NA 259 (25%) NA 248 (19%) NA
  >2 to 5 years 356 (29%) NA 332 (32%) NA 338 (27%) NA
  >5 to 10 years 332 (27%) NA 279 (27%) NA 398 (31%) NA
  >10 to 21 years 153 (13%) NA 172 (17%) NA 288 (23%) NA
Mean 4.9 years NA 5.4 years NA 6.4 years NA
Median 3.9 years NA 4.3 years NA 5.5 years NA
Cost of living adjusted median household income in county of residence £
  First tertile 336 (28%) 10,886 (32%) 291 (28%) 13,642 (33%) 384 (30%) 26,044 (34%)
  Second tertile 436 (36%) 12,059 (36%) 380 (36%) 14,953 (36%) 422 (33%) 27,003 (35%)
  Third tertile 443 (36%) 10,910 (32%) 371 (36%) 12,916 (31%) 466 (37%) 23,208 (30%)
  Median $46,000 $46,000 $45,000 $45,000 $45,000 $45,000
p = 0.0008 p = 0.0008 p < 0.0001
%<High-school education in county of residenceg
  First tertile 517 (43%) 11,703 (35%) 474 (45%) 14,197 (34%) 510 (40%) 25,487 (33%)
  Second tertile 362 (30%) 11,584 (34%) 292 (28%) 14,251 (34%) 384 (30%) 25,826 (34%)
  Third tertile 336 (28%) 10,568 (31%) 276 (26%) 13,063 (31%) 378 (30%) 24,942 (33%)
Median 17% 18% 17% 18% 17% 18%
p < 0.0001 p < 0.0001 p < 0.0001
ap values from Fisher’s Exact Test.
bp < 0.00001 for comparison of NSCLC stage distribution between NSCLC-1 and BC-NSCLC groups.
cFisher’s exact test, with the omission of the unknown variable, changes p values but not the qualitative results (i.e., significant versus not significant) except for distant NSCLC 
histology (p = 0.18) and localized NSCLC grade (p = 0.26), which were no longer significant after omission of “non–small-cell lung cancer” and “unknown” respectively.
dSquamous cell carcinoma (ICD-O-3 8050-8084/3), adenocarcinoma (ICD-O-3 8140/3, 8255/3, 8260/3, 8310/3), bronchiolo-alveolar carcinoma (ICD-O-3 8250-8254/3), 
adenosquamous carcinoma (ICD-O-3 8560/3), large cell carcinoma (ICD-O-3 8012/3), non–small-cell carcinoma (ICD-O-3 8046/3), not otherwise specified. Patients with other 
malignant lung histologies, including neuroendocrine or carcinoid cancers (n = 196), small cell carcinoma (n = 683) or sarcoma (n = 15) were excluded, since the etiologies, natural 
history, treatment, and/or outcomes differ from NSCLC. Unspecified malignant lung carcinomas (n = 484) other than “NSCLC, NOS” were also excluded.
eUnknown breast radiotherapy (see Table 1), and/or unknown breast or lung laterality (n = 4, 6 and 68 for localized, regional, and distant stage NSCLC) not shown.
fNumber of years between breast cancer and NSCLC diagnosis.
gBased upon 2000 census data. For NSCLC-1 patients, 5 patients with localized NSCLC, 1 patient with regional and 1 patient with distant NSCLC had unavailable sociodemographic 
information. For percent population with less than a high-school education, tertiles are: 4–16%, >16–23%, and 23–51%; for cost of living adjusted median household income, tertiles 
are $21,000–$41,000, >$41,000–$48,000, and >$48,000–$80,000.
NA, not applicable (because variable only applies to BC-NSCLC group); NSCLC, non small cell lung cancer.
TABLE 2.  (Continued)
Localizeda Regionala Distanta
BC-NSCLC NSCLC-1 BC-NSCLC NSCLC-1 BC-NSCLC NSCLC-1
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versus NSCLC-1, at least for the first 7 years. Table 5 shows 
the covariate-adjusted mortality comparisons of BC-NSCLC 
versus NSCLC-1 using Cox regression analyses (adjusting 
primarily for NSCLC risk factors) for OS and LC-CSS, and 
cumulative incidence regression for lung cancer mortality. In 
particular, in multivariate models for localized NSCLC, a his-
tory of BC did not significantly impact OS. For regional and 
distant NSCLC, OS of BC-NSCLC was significantly, albeit 
slightly, greater than NSCLC-1. In combination, the results 
obtained for the cause-specific and cumulative incidence 
regression models indicate that BC survivors in each NSCLC 
stage group were significantly (p < 0.0001) less likely to die 
from NSCLC.
Prognostic Factors Affecting OS and LC-
CSS Among BC Survivors with NSCLC
Supplemental Tables 1 and 2, (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A605), summarize the 
multivariate analyses of variables potentially affecting OS and 
LC-CSS, respectively.
Variables related to prior BC diagnosis:
 For localized NSCLC, no clinicopathologic features 
of antecedent BC significantly impacted OS or LC-CSS. 
For regional NSCLC, more advanced BC stage was associ-
ated with improved LC-CSS, although other clinicopatho-
logic BC characteristics did not significantly influence OS 
or LC-CSS. For distant NSCLC, more advanced BC stage, 
ER-positivity, prior mastectomy, and prior breast radiother-
apy were associated with improved LC-CSS; ER-positivity 
was also significantly associated with improved OS. Within 
NSCLC stages, results observed for cumulative incidence 
were generally similar to those for LC-CSS in terms of the 
estimated direction of effect on lung cancer mortality risk 
and statistical significance, ER status being a notable excep-
tion for distant NSCLC.
Variables related to NSCLC diagnosis:
 For each BC-NSCLC stage, favorable prognostic fac-
tors (statistically significant unless otherwise noted) for OS 
and/or LC-CSS included younger age at NSCLC diagnosis, 
NSCLC adenocarcinoma histology (0.05 < p < 0.10 for OS 
TABLE 3.  Vital Status and Cause of Death Among Women with Non–Small-Cell Lung Cancer After Breast Cancer (BC-NSCLC) 
and First Primary NSCLC (NSCLC-1)
Localized Regional Distant
BC-NSCLC NSCLC-1 BC-NSCLC NSCLC-1 BC-NSCLC NSCLC-1
A. All patients:
Alive at last follow-up 654 (54%) 15,040 (44%) 359 (35%) 10,360 (25%) 166 (13%) 6531 (9%)
Deceased 561 (46%) 18,820 (56%) 683 (66%) 31,152 (75%) 1106 (87%) 69,725 (91%)
Cause of deatha
  Lung cancer 259 (46%) 12,478 (66%) 450 (66%) 25,726 (83%) 768 (67%) 61,259 (88%)
  Breast cancer 130 (23%) 103 (0.5%) 123 (18%) 135 (0.4%) 219 (19%) 299 (0.4%)
  Other cancer 27 (5%) 892 (5%) 35 (5%) 986 (3%) 45 (4%) 3722 (5%)
  Heart disease 57 (10%) 1692 (9%) 23 (3%) 1407 (5%) 18 (2%) 1457 (2%)
  Other causes 88 (16%) 3655 (19%) 52 (8%) 2898 (9%) 56 (5%) 2988 (4%)
B. Patients diagnosed with NSCLC from 1988 to 1998:
Alive at last follow-up 33 (18%) 1488 (18%) 14 (8%) 702 (6%) 3 (3%) 134 (0.8%)
Deceased 152 (82%) 6993 (82%) 151 (92%) 10,363 (94%) 113 (97%) 17,331 (99%)
Cause of deatha
  Lung cancer 64 (42%) 4250 (61%) 90 (60%) 8262 (80%) 75 (66%) 15,225 (88%)
  Breast cancer 28 (18%) 48 (0.7%) 29 (19%) 52 (0.5%) 24 (21%) 68 (0.4%)
  Other cancer 6 (4%) 371 (5%) 10 (7%) 365 (4%) 5 (4%) 949 (5%)
  Heart disease 18 (12%) 807 (12%) 8 (5%) 619 (6%) 1 (0.9%) 389 (2%)
  Other causes 36 (24%) 1517 (22%) 14 (9%) 1065 (10%) 8 (7%) 700 (4%)
C. Patients diagnosed with NSCLC from 1999–2009:
Alive at last follow-up 621 (60%) 13,552 (53%) 345 (39%) 9658 (32%) 163 (14%) 6397 (11%)
Deceased 409 (40%) 11,827 (47%) 532 (61%) 20,789 (68%) 993 (86%) 52,394 (89%)
Cause of deatha
  Lung cancer 195 (48%) 8228 (70%) 360 (68%) 17,464 (84%) 693 (70%) 46,034 (88%)
  Breast cancer 102 (25%) 55 (0.5%) 94 (18%) 83 (0.4%) 195 (20%) 231 (0.4%)
  Other cancer 21 (5%) 521 (4%) 25 (5%) 621 (3%) 40 (4%) 2773 (5%)
  Heart disease 39 (10%) 885 (7%) 15 (3%) 788 (4%) 17 (2%) 1068 (2%)
  Other causes 52 (13%) 2138 (18%) 38 (7%) 1833 (9%) 48 (5%) 2288 (4%)
aPercentage estimates for cause of mortality are based upon total number of deaths.
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after regional or distant NSCLC), lower NSCLC grade (not 
significant for OS after localized NSCLC), and the receipt of 
cancer-directed NSCLC surgery.
Notable differences in statistical significance, for the 
cumulative incidence model versus the LC-CSS model, 
occurred for NSCLC grade among both regional and distant 
NSCLC and for NSCLC radiotherapy among regional NSCLC. 
Otherwise, results observed for cumulative incidence were sim-
ilar to those for LC-CSS in terms of the estimated direction of 
effect on lung cancer mortality risk and statistical significance.
Laterality and latency between BC and NSCLC:
 A greater latency between BC and NSCLC diagnoses cor-
related with improved OS and LC-CSS after regional NSCLC 
and worse OS and LC-CSS after distant NSCLC. Laterality of 
NSCLC relative to BC did not significantly influence OS or 
LC-CSS for any NSCLC stage group. Results of cumulative 
incidence analyses were comparable to those for LC-CSS.
Sociodemographic factors:
 White race and lower socioeconomic status were associ-
ated with inferior OS after NSCLC, significantly so after local-
ized NSCLC. White race was associated with significantly worse 
LC-CSS after regional and distant NSCLC, while socioeconomic 
status did not significantly affect LC-CSS. Results for cumulative 
incidence analyses were consistent with those of LC-CSS analyses.
Influence of radiotherapy for BC:
 We performed separate analyses, comparing 
BC-NSCLC women with localized (n = 285) or regional 
(n = 232) NSCLC who had prior radiotherapy for ipsilateral 
BC versus BC-NSCLC women who did not undergo BC 
radiotherapy. For localized NSCLC, prior ipsilateral BC radio-
therapy did not significantly impact LC-CSS (p = 0.26) or OS 
(p = 0.10). For regional NSCLC, prior ipsilateral BC radio-
therapy resulted in increased OS (p = 0.033); the increased 
LC-CSS was not significant (p = 0.08).
DISCUSSION
To our knowledge, this is the first large population-based 
study to describe prognostic features and outcomes for BC 
survivors who develop NSCLC. An important new finding, 
given the strong well established association of NSCLC stage 
with patient survival,39 is the significantly greater likelihood of 
localized NSCLC among BC survivors in contrast to de novo 
NSCLC. This observation may reflect earlier NSCLC detection 
in BC patients, perhaps due to heightened surveillance com-
pared with women in the general population. In contrast, among 
HL survivors who developed NSCLC, no such difference in 
stage was observed,24 although increased surveillance is also 
recommended for these patients.40 Statistically, all-cause mortal-
ity was superior among BC-NSCLC versus NSCLC for regional 
and distant NSCLC, although survival differences were modest. 
Not surprisingly, due to BC deaths, LC-CSS of NSCLC-1 versus 
FIGURE 1.  Kaplan-Meier overall survival for breast cancer-
non-small-cell lung cancer (NSCLC; dashed lines) and NSCLC-1 
(solid lines) women, grouped by NSCLC stage (black, red, and 
green for localized, regional, and distant NSCLC).
TABLE 4.  Comparison of Kaplan-Meier All-Cause Survival 
Probabilities: Women with Non–Small-Cell Lung Cancer 
(NSCLC) After Breast Cancer (BC-NSCLC) Compared with 
First Primary NSCLC (NSCLC-1)
BC-NSCLC NSCLC-1
Localized NSCLC n = 1215 n = 33,860
  6-month survival 92% 90%
  1-year survival 85% 82%
  2-year survival 73% 69%
  5-year survival 50% 48%
  Median survival 5.1 years 4.6 years
p valuea 0.16
p valueb 0.018
Regional NSCLC n = 1042 n = 41,512
  6-month survival 84% 77%
  1-year survival 70% 61%
  2-year survival 49% 42%
  5-year survival 26% 23%
  Median survival 1.9 years 1.5 years
p valuea < 0.0001
p valueb < 0.0001
Distant NSCLC n = 1272 n = 76,256
  6-month survival 49% 43%
  1-year survival 29% 25%
  2-year survival 13% 11%
  5-year survival 6% 3%
  Median survival 5.8 months 4.6 months
p valuea < 0.0001
p valueb < 0.0001
aTwo-tailed log-rank test, NSCLC-1 group compared to BC-NSCLC group.
bSupremum log-rank test, NSCLC-1 group compared to BC-NSCLC group.
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BC-NSCLC was more favorable, but the extent of the difference 
was striking, particularly so with more advanced BC stage.
Overall Survival
While a history of HL portends a significantly worse 
prognosis (hazard ratio = 1.3–1.6) for patients diagnosed with 
NSCLC,32 an antecedent BC diagnosis is not associated with 
similarly poor survival. While this difference may be partially 
attributable to HL survivors experiencing increased deaths 
from other causes,41 it is also possible that immune response 
genes (recently implicated as prognostic for survival after 
NSCLC)42 are more likely to be compromised in HL patients 
than in BC patients. Another recent study showing that survival 
after NSCLC is significantly worse among patients with ante-
cedent CLL compared with patients with first primary NSCLC 
(hazard ratio = 1.19; p < 0.001)25 is also consistent with the 
emerging role of immune response genes in NSCLC survival.42
Radiotherapy for BC
It is important to consider BC radiotherapy, as resultant 
normal tissue damage can limit subsequent therapeutic options 
for BC-NSCLC. Radiotherapy to the ipsilateral chest to treat 
BC did not adversely impact survival outcomes after NSCLC 
and, in fact, appeared to be associated with improved OS 
(p = 0.033) for regional BC-NSCLC, perhaps reflecting a greater 
likelihood of resection in previously irradiated patients. Some 
reports suggest that BC radiotherapy may increase the risk of 
ipsilateral NSCLC, beginning about 10 years after treatment,10–19 
although a recent study of 182,057 U.S. BC survivors (1973–
2000) concluded that 94% of all second cancers, including 
BC-NSCLC, were due to nonradiation factors.19 In a separate 
analysis of SEER program data (1973–2000), among 109,188 
BC patients whose initial course of treatment included radiother-
apy, 1042 developed lung cancer, with standardized incidence 
ratios at <1, 1–4, 5–9, and 10+ years of 0.66, 0.87, 1.09, and 
1.47, respectively.4 Although no investigation to our knowledge 
has examined the molecular genetics of BC-NSCLC, prior stud-
ies of genetic alterations in NSCLC after therapy for HL showed 
a 5.9-fold increase (p = 0.0002) in microsatellite alterations, 
suggestive of genomic instability, compared with first primary 
NSCLC.43 Although outcomes in any patients for whom these 
types of genetic alterations exist may differ from first primary 
NSCLC, our study was not able to address this issue.
Treatment Approaches for NSCLC
Women with localized or regional NSCLC after BC 
were more likely to undergo cancer-directed surgery than 
NSCLC-1 patients. The BC-NSCLC group was less likely to 
undergo radiotherapy for NSCLC, perhaps reflecting concerns 
about thoracic re-irradiation. For regional NSCLC (for which 
radiotherapy is often used even in patients undergoing resec-
tion), 38% of BC-NSCLC versus 49% of NSCLC received 
radiotherapy.
BC and NSCLC characteristics
BC-NSCLC tended to be diagnosed at earlier stages 
(e.g., localized versus more advanced) among women initially 
diagnosed with BC in 2000–2009 compared with 1988–1999. 
This observation may reflect the more common use of radio-
logic imaging in later years.44
ER-positivity in BC was a statistically significant, favor-
able factor influencing OS and LC-CSS for distant NSCLC, 
although its influence was modest. For local and regional 
NSCLC, the effect of ER-positivity on survival outcomes was in 
the same direction, although not statistically significant. Greater 
exposure to cytotoxic drugs in ER-negative BC patients, with 
associated toxicities, could potentially compromise later physi-
cal reserve and the administration of additional therapy for 
NSCLC, providing one explanation for this observation. It is 
also possible that antiestrogen therapy (which can be correlated 
with ER-positivity) modifies lung cancer prognosis.45
A recent SEER-based study raised the possibility of dif-
ferential etiologic factors for NSCLC after ER-positive versus 
ER-negative BC.46 A natural corollary then is whether different 
etiologic influences might also be associated with subsequent 
survival outcomes. These SEER-based findings46 require con-
firmation in analytic studies with detailed tumor characteris-
tics and lifestyle risk factor information. Nonetheless, results 
of the recent large-scale Collaborative Oncological Gene-
Environment Study underscored that multiple genomic regions 
TABLE 5.  Covariate-Adjusted Mortality Comparisons of Women with Non–Small-Cell Lung Cancer with (NSCLC) with and 
Without Prior Breast Cancer Diagnosis: Impact of Breast Cancer History on All-Cause Mortality Rate, Lung-Cancer Specific 
Mortality Rate, and Cumulative Incidence Of Lung-Cancer Death
Localized NSCLC Regional NSCLC Distant NSCLC
β (95% CI); p Value β (95% CI); p Value β (95% CI); p Value
All-cause mortality ratea −0.04 (−0.04 to 0.13); p = 0.28 −0.08 (−0.02 to −0.16); p = 0.016 −0.15 (−0.09 to −0.21); p < 0.0001
Lung cancer cause-specific mortality 
ratea
−0.43 (−0.30 to 0.56); p < 0.0001 −0.31 (−0.13 to −0.42); p < 0.0001 −0.39 (−0.31 to −0.46); p < 0.0001
Cumulative incidence for lung cancer 
mortality b
−0.54 (−0.43 to −0.67); p < 0.0001 −0.40 (−0.31 to −0.49); p < 0.0001 −0.49 (−0.43 to −0.56); p < 0.0001
aRegression parameter (β), confidence interval (CI), and p values for all-cause and lung-cancer cause-specific mortality rate analyses derived from Cox proportional hazards models 
that include history of BC, age at NSCLC diagnosis, calendar year of NSCLC diagnosis, radiotherapy for NSCLC, cancer-directed surgery for NSCLC, NSCLC grade, and NSCLC 
histology group, race, and education and income of county of residence. As these models primarily reflect risk factors among the NSCLC-1 population (which greatly exceeded the 
number of patients with NSCLC after breast cancer), we do not report the results for the other included variables.
bRegression parameter (β), CI, and p value for cumulative incidence of lung cancer mortality is derived from the proportional subdistribution hazard model introduced in Fine and 
Gray (1999). These models also primarily reflect risk factors among the NSCLC-1 population, so we do not report the results for the other included variables.
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are pleiotropic for several cancer types47 and highlighted the 
importance of genetic approaches in making inroads into both 
SMN etiology and subsequent outcomes.
Demographic Features
The well established association of BC with higher 
sociodemographic status and white race48,49 likely accounts for the 
slight overrepresentation of these features among BC-NSCLC 
patients versus NSCLC-1 patients. Non-white race as a positive 
prognostic factor for LC-CSS after BC-NSCLC may be partially 
attributable to more favorable outcomes among Asian women 
(included in this category) who tend to harbor EGFR mutations, 
but may also reflect the small number of black patients in our 
study. Although the county-based sociodemographic attributes 
were predictive for OS (statistically significant among those 
with localized NSCLC), LC-CSS was not significantly affected.
Deaths Due to Other Causes
Although we did not quantify mortality due to cardio-
vascular disease (CVD), the number of deaths due to CVD (n 
= 98) was an order of magnitude smaller than NSCLC (n = 
1477). Radiotherapy for BC is associated with excess heart dis-
ease,50 with a significant dose-response relationship reported 
in a European study of women treated with older technologies 
(1958–2001) and resultant larger radiation dose-volume car-
diac exposure.51 Although the relative number of CVD deaths 
in our more contemporary, US-based population was modest, 
it should be kept in mind that we studied outcomes only in 
survivors who developed NSCLC, not all patients.
Strengths and Limitations
Strengths of the current study include the sizable num-
ber of women (n = 3529) identified in a large population-based 
setting, which allowed for analyses of outcomes according to 
NSCLC stage and other patient-related and tumor-related vari-
ables. Limitations of registry-based studies,31 such as this one, 
include the absence of detail with regard to radiotherapy doses/
fields, chemotherapy, and individual data on factors that could 
influence NSCLC survival, including smoking, weight loss, 
performance status, and sociodemographic status.52 While we 
accounted for latency between BC and NSCLC in our survival 
analyses, it should be noted that 83% of BC-NSCLC were diag-
nosed <10 years after BC, and therefore unlikely to be signifi-
cantly associated with the prior administration of radiation. Also, 
while SEER program registries are selected to be representative 
of the US population, results based on analyses of SEER-based 
data may not necessarily apply to the population from counties 
and states that do not participate in SEER. In addition, it should 
be kept in mind that data obtained from death certificates (used to 
determine CSS) may be subject to misclassification. Despite these 
limitations, other SEER-based studies have provided important 
information with regard to the survival of NSCLC patients who 
were previously diagnosed with either HL or CLL.24,25
CONCLUSIONS
Given the mortality and morbidity associated with 
NSCLC, efforts at smoking cessation (a known modifiable risk 
factor) should be strongly urged in BC survivors. Although 
the strong effect of stage on survival after diagnosis of pri-
mary NSCLC is well established,39 results of our large pop-
ulation-based study now also confirm this stage dependence 
after BC-NSCLC, as described in a small retrospective study 
of 35 patients,23 and as also shown for NSCLC after HL.24 
Recommendations for risk assessment, risk reduction, and 
screening for SMN in cancer survivors were recently sum-
marized by Wood et al.29 Importantly, cancer survivors con-
sidered at high risk for second primary lung cancers were 
those who also met criteria used in the National Lung 
Screening Trial (NLST) of low-dose computed tomography 
(CT): current smokers [>30 pack-years] and former smokers 
[>30 pack-years and quit <15 years ago].53 For these cancer 
survivors, annual low-dose spiral CT was recommended,29 
given the NLST findings of significantly reduced lung can-
cer-specific mortality in subjects screened with CT versus 
traditional chest radiography.53 Based on NLST findings,53 
the American Association of Thoracic Surgery also recently 
released recommendations that patients 55–79 years of age 
with a 30+ pack year smoking history should undergo annual 
low-dose CT screening for lung cancer.54 Clinicians involved 
in survivorship care should be attentive to ensure that cancer 
screening guidelines used in the general population55 are also 
applied to BC survivors who meet eligibility criteria.29 In the 
interim, future research that addresses the clinical and bio-
logic underpinnings of NSCLC that develops after BC may 
also provide an opportunity to further understand the etiology 
and pathogenesis of first primary lung cancers.
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